Umbralisib, a Dual PI3Kd/CK1e Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. (2021)
Attributed to:
Joint Wellcome and MRC Centre, ‘Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute’
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.66083
Publication URI: https://www.repository.cam.ac.uk/handle/1810/318964
Type: Journal Article/Review